We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
-8.38%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$142M
AUM Growth
-$146M
Cap. Flow
-$115M
Cap. Flow %
-80.89%
Top 10 Hldgs %
99.21%
Holding
14
New
1
Increased
5
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
PVLA
Palvella Therapeutics
PVLA
+$7.29M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$1.64M
3
QURE icon
uniQure
QURE
+$1.53M
4
PRQR icon
ProQR Therapeutics
PRQR
+$661K
5
BCYC
Bicycle Therapeutics
BCYC
+$253K

Top Sells

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$14.8M
2
FATE icon
Fate Therapeutics
FATE
+$10.2M
3
SYBX
Synlogic
SYBX
+$9.5M
4
MRUS
Merus
MRUS
+$5.79M

Sector Composition

Rank Sector Weight
1 Healthcare 62.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$38.1M 26.85%
500,000
– –
MRUS
2
DELISTED
Merus
MRUS
$18.5M 13.04%
1,038,746
-352,751
-25% -$5.79M
QURE icon
3
CALL
uniQure
QURE
$3.22B
$15.7M 11.09%
+400,000
New +$23.1M
QURE icon
4
uniQure
QURE
$3.22B
$15.4M 10.84%
391,199
+26,603
+7% +$1.53M
SPRO icon
5
Spero Therapeutics
SPRO
$73M
$12.2M 8.62%
1,154,356
– –
PVLA
6
Palvella Therapeutics
PVLA
$2.27B
$10.1M 7.1%
36,978
+18,830
+104% +$7.29M
BCYC
7
Bicycle Therapeutics
BCYC
$292M
$8.74M 6.15%
767,026
+29,497
+4% +$253K
LKFT
8
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$8.68M 6.11%
56,840
+10,000
+21% +$1.64M
XENE icon
9
Xenon Pharmaceuticals
XENE
$6.12B
$8.57M 6.04%
951,527
– –
PRQR icon
10
ProQR Therapeutics
PRQR
$265M
$4.79M 3.37%
831,661
+82,800
+11% +$661K
FATE icon
11
Fate Therapeutics
FATE
$326M
$1.12M 0.79%
72,273
-529,823
-88% -$10.2M
ARWR icon
12
Arrowhead Research
ARWR
$12.4B
– –
-557,455
Closed -$14.8M
IBB icon
13
PUT
iShares Biotechnology ETF
IBB
$9.71B
– –
-1,000,000
Closed -$109M
SYBX
14
DELISTED
Synlogic
SYBX
– –
-69,595
Closed -$9.5M

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Aquilo Capital Management held 14 positions worth $142M, down 51% from $288M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Aquilo Capital Management withdrew a net $115M in Q3 2019, closing 3 positions and reducing 2 holdings. Its most notable exit was Arrowhead Research, an estimated $14.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, up from 47% a quarter earlier.

Against the trend, Aquilo Capital Management added an estimated $7.29M to Palvella Therapeutics.

  • Aquilo Capital Management added most to Palvella Therapeutics in Q3 2019, an estimated $7.29M increase.
  • Aquilo Capital Management's biggest Q3 2019 reduction was Fate Therapeutics, cutting an estimated $10.2M.
  • Aquilo Capital Management fully exited Arrowhead Research in Q3 2019, selling an estimated $14.8M.
  • Aquilo Capital Management's ten largest holdings make up 99% of its $142M portfolio in Q3 2019.
  • Aquilo Capital Management opened 1 new position and closed 3 in Q3 2019.
  • Aquilo Capital Management's portfolio value fell 51% quarter-over-quarter to $142M.

Based on Aquilo Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.